Key terms
About CSTL
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CSTL news
Yesterday
5:23pm ET
Castle Biosciences Secures Loan and Reshuffles Board
Mar 20
4:55am ET
Castle Biosciences management to meet virtually with Stephens
Mar 15
3:32pm ET
Castle Biosciences management to meet virtually with Stephens
Mar 11
2:15am ET
Castle Biosciences: A Strong Buy on Genomic Diagnostic Leadership and Market Growth Potential
Mar 07
7:24am ET
Castle’s DecisionDx-SCC study shows predictive accurracy with patients
Mar 06
4:55am ET
Castle Biosciences management to meet with KeyBanc
Mar 05
8:01am ET
Castle Biosciences management to meet with KeyBanc
Mar 01
7:09am ET
Castle Biosciences price target raised to $37 from $33 at Scotiabank
Mar 01
6:33am ET
Castle Biosciences price target raised to $28 from $25 at KeyBanc
Mar 01
1:01am ET
Outperform Rating for Castle Biosciences Amid Strong Market Presence and Growth Prospects
Feb 29
9:00am ET
Analysts Conflicted on These Healthcare Names: Castle Biosciences (CSTL), DENTSPLY SIRONA (XRAY) and Silk Road Medical (SILK)
Feb 29
8:02am ET
Analysts Conflicted on These Healthcare Names: Immunocore Holdings (IMCR), Voyager Therapeutics (VYGR) and Castle Biosciences (CSTL)
Feb 29
6:49am ET
Castle Biosciences price target raised to $33 from $31 at Baird
Feb 28
5:27pm ET
Castle Biosciences files $300M mixed securities shelf
Feb 28
4:26pm ET
Castle Biosciences sees FY24 revenue $235M-$240M, consensus $214.7M
Feb 28
4:26pm ET
Castle Biosciences reports Q4 EPS (10c), consensus (54c)
Feb 28
4:23pm ET
Castle Biosciences Shapes Dialogue with Strategic Presentations
Jan 18
7:13am ET
Castle study shows DecisionDx -SCC test to guide radiation in cSCC reduces cost
Jan 15
8:18am ET
Castle presents data supporting utility of tests in care of skin cancer patients
Jan 09
12:57am ET
Buy Rating Affirmed for Castle Biosciences on Strong Performance and Positive Outlook
Jan 08
8:50am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jan 08
7:18am ET
Scotiabank Reaffirms Their Buy Rating on Castle Biosciences (CSTL)
Jan 07
8:05pm ET
Castle Biosciences reports preliminary FY23 revenue $210M, consensus $203.95M
Jan 07
5:26am ET
BTIG Reaffirms Their Buy Rating on Castle Biosciences (CSTL)
Jan 02
9:08am ET
BTIG Keeps Their Buy Rating on Castle Biosciences (CSTL)
Dec 31
5:11am ET
BTIG Sticks to Their Buy Rating for Castle Biosciences (CSTL)
No recent news articles are available for CSTL
No recent press releases are available for CSTL
CSTL Financials
Key terms
Ad Feedback
CSTL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CSTL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range